Fas/FasL mediates NF-κBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
12 05 2021
12 05 2021
Historique:
received:
30
01
2021
accepted:
19
04
2021
revised:
15
04
2021
entrez:
13
5
2021
pubmed:
14
5
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Fas/Fas ligand (FasL)-mediated cell apoptosis involves a variety of physiological and pathological processes including chronic hepatic diseases, and hepatocytes apoptosis contributes to the development of liver fibrosis following various causes. However, the mechanism of the Fas/FasL signaling and hepatocytes apoptosis in liver fibrogenesis remains unclear. The Fas/FasL signaling and hepatocytes apoptosis in liver samples from both human sections and mouse models were investigated. NF-κBp65 wild-type mice (p65
Identifiants
pubmed: 33980818
doi: 10.1038/s41419-021-03749-x
pii: 10.1038/s41419-021-03749-x
pmc: PMC8115181
doi:
Substances chimiques
Fas Ligand Protein
0
NF-kappa B
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
474Références
Cell Rep. 2014 Apr 10;7(1):45-52
pubmed: 24685133
Cell Death Dis. 2019 Oct 3;10(10):748
pubmed: 31582729
Nat Commun. 2018 Feb 5;9(1):493
pubmed: 29402958
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1205-10
pubmed: 18996088
Cell Res. 2015 Aug;25(8):930-45
pubmed: 26169608
Hepatology. 2016 Oct;64(4):1217-31
pubmed: 27396433
Hepatology. 2011 Jan;53(1):230-42
pubmed: 20979056
J Clin Invest. 2018 Jan 2;128(1):531-544
pubmed: 29227280
Cell Death Dis. 2020 Sep 22;11(9):785
pubmed: 32963220
Autophagy. 2013 Aug;9(8):1131-58
pubmed: 23774882
Cell Death Differ. 2017 Sep;24(9):1478-1487
pubmed: 28622296
Cell Death Differ. 2009 Sep;16(9):1192-202
pubmed: 19444283
Protein Cell. 2014 Oct;5(10):737-49
pubmed: 25073422
Free Radic Biol Med. 2015 Oct;87:69-83
pubmed: 26119788
Science. 2010 Dec 3;330(6009):1390-3
pubmed: 21127253
Transplant Proc. 2010 Jun;42(5):1550-6
pubmed: 20620473
Cells. 2015 Oct 05;4(4):596-621
pubmed: 26445063
Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):108-18
pubmed: 21293511
FASEB J. 2019 Feb;33(2):2000-2016
pubmed: 30216111
J Hepatol. 2017 Jul;67(1):100-109
pubmed: 28267623
Br J Pharmacol. 2020 Jun;177(12):2830-2847
pubmed: 32017042
Am J Physiol Gastrointest Liver Physiol. 2015 May 15;308(10):G807-30
pubmed: 25767261
J Cell Biochem. 2017 Aug;118(8):2463-2473
pubmed: 28133777
J Immunol. 2018 Mar 15;200(6):2004-2012
pubmed: 29436413
Gut. 2010 May;59(5):655-65
pubmed: 20427400
J Pathol. 2012 Jan;226(2):255-73
pubmed: 21990109
J Clin Invest. 2013 May;123(5):1887-901
pubmed: 23635787
Oncogene. 2008 Dec;27 Suppl 1:S71-83
pubmed: 19641508
FASEB J. 2009 Jun;23(6):1625-37
pubmed: 19141537
J Clin Invest. 2013 May;123(5):1902-10
pubmed: 23635788
Cell Death Dis. 2014 Mar 13;5:e1128
pubmed: 24625987
Nat Med. 2016 Apr;22(4):334-5
pubmed: 27050582
Nature. 2009 Sep 10;461(7261):282-6
pubmed: 19741708
Cell Rep. 2017 Mar 7;18(10):2373-2386
pubmed: 28273453
Cell Cycle. 2009 Sep 1;8(17):2692-6
pubmed: 19652530
Cancer Cell. 2012 Feb 14;21(2):150-4
pubmed: 22340589
Mol Cancer Ther. 2010 Aug;9(8):2220-31
pubmed: 20682655
Hepatology. 2013 Oct;58(4):1461-73
pubmed: 23553591
J Hepatol. 2015 Sep;63(3):670-8
pubmed: 25908269
Hepatology. 2012 Nov;56(5):1902-12
pubmed: 22544759
Nat Commun. 2013;4:2174
pubmed: 23873265
J Hepatol. 2016 Mar;64(3):618-27
pubmed: 26471504
Cell Res. 2009 Nov;19(11):1269-78
pubmed: 19668263
Hepatology. 2010 Apr;51(4):1226-36
pubmed: 20099303
Autophagy. 2015;11(9):1623-35
pubmed: 26212789
Gut. 2015 May;64(5):830-41
pubmed: 25681399
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Arch Biochem Biophys. 2012 Feb 1;518(1):2-7
pubmed: 22182753
Gastroenterology. 2008 Aug;135(2):601-9
pubmed: 18582468
Cell Cycle. 2015;14(11):1631-42
pubmed: 25927598
Blood. 2015 May 21;125(21):3273-80
pubmed: 25847014